INPLASY PROTOCOL

To cite: Wei et al. Adjunctive antidepressants for COVID-19: a systematic review. Inplasy protocol 202210030. doi: 10.37766/inplasy2022.1.0030

Received: 07 January 2022

Published: 07 January 2022

Corresponding author:
Yu-tao Xiang

xyutly@gmail.com

Author Affiliation:
University of macau.

Support: **None.**

Review Stage at time of this submission: **Preliminary searches.**

Conflicts of interest:
None declared.

Adjunctive antidepressants for COVID-19: a systematic review

Wei, Z[1]; Cai, H[2]; Sun, H[3]; Xiang, Y[4].

Review question / Objective: **To systematically examine the efficacy and safety of antidepressants added to treatment as usual (TAU) for patients suffering from COVID-19.**
Condition being studied: **Preliminary evidence showed that certain antidepressants appear to have potential as safe, inexpensive, and widely available medications that could improve COVID- 19-related outcomes such as mortality. Therefore, this systematic review will examine the efficacy and safety of antidepressants added to treatment as usual (TAU) for patients suffering from COVID-19.**
Information sources: **CNKI, WanFang, PsycINFO, Cochrane Library, PubMed, and EMBASE.**

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 07 January 2022 and was last updated on 07 January 2022 (registration number INPLASY202210030).

INTRODUCTION

Review question / Objective: **To systematically examine the efficacy and safety of antidepressants added to treatment as usual (TAU) for patients suffering from COVID-19.**

Condition being studied: **Preliminary evidence showed that certain antidepressants appear to have potential as safe, inexpensive, and widely available medications that could improve COVID- 19-related outcomes such as mortality. Therefore, this systematic review will examine the efficacy and safety of**

antidepressants added to treatment as usual (TAU) for patients suffering from COVID-19.

METHODS

Search strategy: Chinese Journal Net, WanFang, PsycINFO, Cochrane Library, PubMed, and EMBASE databases will be independently searched by two authors for studies on adjunctive antidepressants for COVID-19, from their inceptions until December 9, 2021 using the following search terms: (Coronavirus OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV OR coronavirus disease 2019) AND (agomelatine OR amitriptyline OR bupropion OR citalopram OR clomipramine OR desvenlafaxine OR duloxetine OR escitalopram OR fluoxetine OR fluvoxamine OR levomilnacipran OR milnacipran OR mirtazapine OR nefazodone OR paroxetine OR reboxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR vortioxetin OR antidepressive agents).

Participant or population: Patients suffering from COVID-19.

Intervention: Treatment as usual (TAU) plus antidepressants.

Comparator: TAU or placebo or not applicable.

Study designs to be included: Original studies including randomized control trials (RCTs), observational studies and retrospective studies.

Eligibility criteria: All types of studies that examined the efficacy and safety of antidepressants added to treatment as usual (TAU) for patients with COVID-19 will be included.

Information sources: CNKI, WanFang, PsycINFO, Cochrane Library, PubMed, and EMBASE.

Main outcome(s): Clinical improvement/ deterioration and all-cause mortality.

Quality assessment / Risk of bias analysis: Quality of RCTs will be assessed using Cochrane risk of bias (Higgins et al., 2011). Other comparative studies will be assessed using the Newcastle-Ottawa Scale (NOS), if applicable.

Strategy of data synthesis: Non applicable.

Subgroup analysis: Non applicable.

Sensitivity analysis: Non applicable.

Country(ies) involved: Macau.

Keywords: Antidepessants; fluvoxamine; COVID-19; systematic review.

Contributions of each author:
Author 1 - Zheng Wei.
Email: zhengwei0702@163.com
Author 2 - Hong Cai.
Email: 591854676@qq.com
Author 3 - Heli Sun.
Email: helisun@um.edu.mo
Author 4 - Yu-tao Xiang.
Email: xyutly@gmail.com